Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. People with type 2 diabetes and obesity who are taking the drugs are also less likely to die ...

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. People with type 2 ...

THEY’VE been hailed as miracle weight-loss jabs – but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called “skinny pens” may also ...

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 percent lower in patients who took semaglutide compared to those who took ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Key Takeaways. Semaglutide significantly reduces ADRD risk compared to insulin, metformin, and older GLP-1RAs in type 2 diabetes patients. The study used a target trial emulation approach with ...

But up to half of all dementia cases might be preventable, and scientists have identified over a dozen modifiable risk factors that contribute to dementia risk, including obesity, type 2 diabetes ...

Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...